表紙:顧みられない熱帯病治療の世界市場-2022-2029年
市場調査レポート
商品コード
1153807

顧みられない熱帯病治療の世界市場-2022-2029年

Global Neglected Tropical Disease Treatment Market - 2022-2029

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
顧みられない熱帯病治療の世界市場-2022-2029年
出版日: 2022年11月15日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場の概要

顧みられない熱帯病治療の世界市場規模は、予測期間(2022-2029年)にCAGR5.55%で成長すると予測されています。

顧みられない熱帯病(NTD)は、主に熱帯地域で見られる20の疾患であり、貧しい人々や女性、子どもたちに不釣り合いな影響を及ぼしています。これらの疾患により、人々は健康面、社会面、経済面でひどい影響を受けています。顧みられない熱帯病(NTDs)の多くは、既存の薬で治療が可能です。ある種の治療法は適用が簡単で、専門医を使う必要がありません。一方、薬物療法はいくつかのNTDsで利用可能ですが、最も必要としている人々に必ずしも届いているとは限りません。

市場力学

顧みられない熱帯病治療市場の成長の背景には、世界の組織による取り組み、先進国における移民人口の増加、発展途上国における適切な衛生環境と意識の欠如など、いくつかの要因が挙げられます。

顧みられない熱帯病に対する創薬への資金提供の増加は、市場成長の原動力になると予想されます。

顧みられない熱帯病とその他の疾患への投資のバランスを取るための最近の国際的な取り組みが、状況を変化させ始めています。例えば、第1回年次報告書によると、推定される資金ギャップは年間3億米ドルです。第3次進捗報告書によると、製薬会社は2020年まで10の疾患に対して178億米ドル相当の医薬品を提供することを約束しています。さらに、WHOは最近、オンコセルカ症(河川失明症)とリンパ系フィラリア症(象皮病)という2つの壊滅的な感染性NTDsの撲滅を支援する1億米ドルの基金の設立を歓迎しました。アブダビ皇太子とビル&メリンダ・ゲイツ財団がそれぞれ2,000万米ドルを拠出し、残りの6,000万米ドルは他のドナーや財団との協力によって調達されます。以上のことから、本市場は予測期間において牽引役となることが期待されます。

抑制要因

顧みられない熱帯病(Neglected Tropical Disease)の治療法の認知度が低いため、売上が減少しています。顧みられない熱帯病は、最先端の医薬品が入手できず、ヘルスケアシステムも不十分です。このため、予測期間中は上記のような要因が阻害要因となることが予想されます。

産業分析

顧みられない熱帯病治療市場は、ポーターファイブフォース、サプライチェーン、価格分析、規制当局の承認など、様々な産業要因に基づく市場の詳細な分析を提供します。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 顧みられない熱帯病に対する創薬資金の増加により、市場の成長が期待されます。
    • 抑制要因
      • 認知度の低さにより、予測期間中に市場成長が阻害されると予想されます。
    • 市場機会
    • 影響分析

第5章 産業分析

  • ポーターの5つの力
  • アンメットニーズ
  • サプライチェーン
  • プライシング分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 疾患タイプ別

  • ブルーリ潰瘍
  • シャーガス病
  • デング熱・チクングニア
  • ドラキュラ症
  • エキノコックス症
  • 食中毒トレマトディアーズ
  • ヒトアフリカトリパノソーマ症
  • リーシュマニア症
  • ハンセン病
  • リンパ系フィラリア症
  • 菌糸腫、黒色ブラストミセス症
  • オンコセルカ症
  • 狂犬病
  • 疥癬(かいせん
  • 住血吸虫症
  • 土壌伝染性蠕虫疾患
  • 蛇咬斑
  • タエニア症/嚢虫症
  • トラコーマ
  • ヨーヨー

第8章 治療タイプ別

  • 薬物療法
  • ワクチン

第9章 販売チャネル別

  • 病院内薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A(合併・買収)分析

第12章 企業プロファイル

  • Bayer AG
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • Cipla Limited
  • AbbVie Inc.
  • Takeda Pharmaceuticals
  • Serum Institute of India
  • Visterra Inc.

第13章 顧みられない熱帯病治療の世界市場-DataM

目次
Product Code: DMPH1231

Market Overview

The global neglected tropical disease treatment market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.55% during the forecast period (2022-2029).

Neglected tropical diseases (NTDs) are a series of 20 diseases mostly found in tropical areas, disproportionately impacting poor people, women and children. People suffer from terrible health, societal, and economic effects due to these disorders. Many neglected tropical diseases (NTDs) are curable with existing medications. Certain therapies are simple to apply and do not necessitate the use of medical specialists. In contrast, while medication therapies are available for several NTDs, they do not always reach the people who need them the most.

Market Dynamics

The neglected tropical disease treatment market growth is driven by several factors, such as initiatives taken by several organizations globally, increase in migrant population in developed nations, and a lack of proper sanitation and awareness in developing countries.

Increasing funding for drug discovery for the neglected tropical disease is expected to drive market growth.

Recent international efforts to balance the investment between neglected and other diseases have begun reshaping the landscape. For instance, according to the first annual report, the estimated financing gap is $300 million per year. According to the third progress report, pharmaceutical companies have pledged medications worth $17.8 billion for the ten diseases until 2020. Moreover, WHO recently welcomed the establishment of a $100 million fund to aid in eradicating two devastating infectious NTDs: onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis). The Crown Prince of Abu Dhabi and the Bill and Melinda Gates Foundation have each pledged US$20 million, with the remaining US$60 million generated through collaboration with other donors and foundations. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint

Lack of awareness cause sales of neglected tropical disease treatment options to fall. These nations lack access to cutting-edge drugs and an inadequate healthcare system. Thus, the abovementioned factors are expected to get hampered in the forecast period.

Industry Analysis

The neglected tropical disease treatment market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis, regulatory approvals etc.

Segment Analysis

Medication segment is expected to hold the largest market share in neglected tropical disease treatment market.

The medication segment accounted for the largest market share in 2021. The segment is further sub-segmented into antibiotic, antiparasitic, anti-inflammatory, anti-microbial, and anti-fungal. Among medications, antiparasitic drugs are most commonly used for treating neglected tropical diseases, as many of them are caused by parasitic transmission. The high prevalence of parasite-infected diseases in remote and rural areas and urban slums due to poor sanitation practices have increased the demand for antiparasitic drugs. Several FDA-approved antiparasitic drugs are on the market to treat neglected tropical diseases, and many major players are developing new and advanced medicines for faster treatment. For instance, on November 8, 2021, Orlando, Fla-based Profounda announced the Food and Drug Administration (FDA) approved an Orphan Drug Designation for the use of the company's therapy, miltefosine (Impavido), to treat invasive candidiasis. Miltefosine is an oral, FDA-approved treatment for visceral, mucosal, and cutaneous leishmaniasis in individuals aged 12 and up. Thus, from the above statements, the markert segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global neglected tropical disease treatment market

North America accounted for the largest market share in 2021. Owing to the highly aware population, advanced healthcare infrastructure, favorable government initiatives, increase in migrant population over the region and presence of major companies. North America has the requisite insect vectors, the climate, and the ecology to support the presence of these diseases and, of course, a susceptible human population to become infected. North America has the requisite insect vectors, the climate, and the ecology to support the presence of these diseases and, of course, a susceptible human population to become infected. According to the Centers for Disease Control and Prevention (CDC), Chagas disease is the new HIV in the U.S., with around 300,000 people suffering from it and about 315 babies born with it yearly. Moreover, in March 2019, Novartis joined the Global Chagas Disease Coalition and announced the first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the neglected tropical disease treatment market are: Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., Cipla Limited, AbbVie Inc., Takeda Pharmaceuticals, Serum Institute of India and, Visterra Inc.

Bayer AG:

Overview:

Bayer is a Life Science company with a more than 150-year history and core health care and agriculture competencies. The Bayer Group is managed as a life science company with three divisions Pharmaceuticals, Consumer Health and Crop Science, which are also our reporting segments. The Enabling Functions support the operational business. In 2019, the Bayer Group comprised 392 consolidated companies in 87 countries. The Pharmaceuticals division focuses on prescription products, especially cardiology and women's healthcare, and specialty therapeutics in oncology, hematology and ophthalmology. The Consumer Health division markets mainly nonprescription (OTC) products in the dermatology, nutritional supplement, analgesic, digestive health, cold, allergy, sinus and flu categories.

Product Portfolio:

Praziquantel (Biltricide): This medication is used to treat infections of certain parasites (such as Schistosoma and liver flukes). Curing parasitic infections helps to improve your health and quality of life. Praziquantel belongs to a class of drugs known as anthelmintics. It works by killing the parasites.

The global neglected tropical disease treatment market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing funding for drug discovery for the neglected tropical disease is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness are expected to get hampered in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply Chain
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type Segment
  • 7.2. Buruli Ulcer*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Chagas Disease
  • 7.4. Dengue and Chikungunya
  • 7.5. Dracunculiasis
  • 7.6. Echinococcosis
  • 7.7. Foodborne Trematodiases
  • 7.8. Human African Trypanosomiasis
  • 7.9. Leishmaniasis
  • 7.10. Leprosy
  • 7.11. Lymphatic Filariasis
  • 7.12. Mycetoma, Chromoblastomycosis
  • 7.13. Onchocerciasis
  • 7.14. Rabies
  • 7.15. Scabies
  • 7.16. Schistosomiasis
  • 7.17. Soil-transmitted Helminthiases
  • 7.18. Snakebite Envenoming
  • 7.19. Taeniasis/Cysticercosis
  • 7.20. Trachoma
  • 7.21. Yaws

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Medication*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Vaccines

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail pharmacies
  • 9.4. Online pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Bayer AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. F. Hoffmann-La Roche Ltd.
  • 12.3. GlaxoSmithKline Plc
  • 12.4. Novartis AG
  • 12.5. Pfizer Inc.
  • 12.6. Cipla Limited
  • 12.7. AbbVie Inc.
  • 12.8. Takeda Pharmaceuticals
  • 12.9. Serum Institute of India
  • 12.10. Visterra Inc.

LIST NOT EXHAUSTIVE

13. Global Neglected Tropical Disease Treatment Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us